Literature DB >> 23002357

Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?

Daniel Smyk1, Eirini I Rigopoulou, Yoh Zen, Robin Daniel Abeles, Charalambos Billinis, Albert Pares, Dimitrios P Bogdanos.   

Abstract

Primary biliary cirrhosis (PBC) is a progressive cholestatic liver disease characterized by the immune-mediated destruction of biliary epithelial cells in small intrahepatic bile ducts. The disease is characterized by circulating antimitochondrial antibodies (AMAs) as well as disease-specific antinuclear antibodies, cholestatic liver function tests, and characteristic histological features, including granulomas. A variety of organisms are involved in granuloma formation, of which mycobacteria are the most commonly associated. This has led to the hypothesis that mycobacteria may be involved in the pathogenesis of PBC, along with other infectious agents. Additionally, AMAs are found in a subgroup of patients with mycobacterial infections, such as leprosy and pulmonary tuberculosis. Antibodies against species-specific mycobacterial proteins have been reported in patients with PBC, but it is not clear whether these antibodies are specific for the disease. In addition, data in support of the involvement of the role of molecular mimicry between mycobacterial and human mitochondrial antigens as triggers of cross-reactive immune responses leading to the loss of immunological tolerance, and the induction of pathological features have been published. Thus, antibodies against mycobacterial heat shock protein appear to cross-recognize AMA-specific autoantigens, but it is not clear whether these autoantibodies are mycobacterium-species-specific, and whether they are pathogenic or incidental. The view that mycobacteria are infectious triggers of PBC is intriguing, but the data provided so far are not conclusive.

Entities:  

Keywords:  Antimitochondrial antibodies; Autoantibody; Autoimmunity; Cholestasis; Heat shock; Infection; Liver disease; Liver failure; Mycobacterium; Tuberculosis

Mesh:

Substances:

Year:  2012        PMID: 23002357      PMCID: PMC3447267          DOI: 10.3748/wjg.v18.i35.4855

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  142 in total

Review 1.  Molecular mimicry and primary biliary cirrhosis: premises not promises.

Authors:  J Van de Water; H Ishibashi; R L Coppel; M E Gershwin
Journal:  Hepatology       Date:  2001-04       Impact factor: 17.425

2.  Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease.

Authors:  Yun Ma; Manabu Okamoto; Mark G Thomas; Dimitrios P Bogdanos; Agnel R Lopes; Bernard Portmann; James Underhill; Ralf Dürr; Giorgina Mieli-Vergani; Diego Vergani
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

3.  Natural history of early primary biliary cirrhosis.

Authors:  J V Metcalf; H C Mitchison; J M Palmer; D E Jones; M F Bassendine; O F James
Journal:  Lancet       Date:  1996-11-23       Impact factor: 79.321

4.  Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.

Authors:  E J Heathcote
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

5.  Polyspecificity of human monoclonal antibodies reactive with Mycobacterium leprae, mitochondria, ssDNA, cytoskeletal proteins, and the acetylcholine receptor.

Authors:  D B Duggan; C Mackworth-Young; A Kari-Lefvert; J Andre-Schwartz; D Mudd; K P McAdam; R S Schwartz
Journal:  Clin Immunol Immunopathol       Date:  1988-12

6.  Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.

Authors:  Phunchai Charatcharoenwitthaya; Sylvania Pimentel; Jayant A Talwalkar; Felicity T Enders; Keith D Lindor; Ruud A F Krom; Russell H Wiesner
Journal:  Liver Transpl       Date:  2007-09       Impact factor: 5.799

7.  Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection.

Authors:  D P Bogdanos; H Baum; P Butler; E I Rigopoulou; E T Davies; Y Ma; A K Burroughs; D Vergani
Journal:  Dig Liver Dis       Date:  2003-11       Impact factor: 4.088

Review 8.  The causes of primary biliary cirrhosis: Convenient and inconvenient truths.

Authors:  M Eric Gershwin; Ian R Mackay
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

9.  Antimitochondrial (pyruvate dehydrogenase) antibodies in leprosy.

Authors:  B Gilburd; L Ziporen; D Zharhary; M Blank; N Zurgil; M A Scheinberg; L H Guedes; M E Gershwin; Y Shoenfeld
Journal:  J Clin Immunol       Date:  1994-01       Impact factor: 8.317

10.  The autoepitope of the 74-kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyltransferase.

Authors:  J Van de Water; M E Gershwin; P Leung; A Ansari; R L Coppel
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

View more
  3 in total

Review 1.  Complexities in the relationship between infection and autoimmunity.

Authors:  Robert Root-Bernstein; DeLisa Fairweather
Journal:  Curr Allergy Asthma Rep       Date:  2014-01       Impact factor: 4.806

Review 2.  The Role of Invariant NKT in Autoimmune Liver Disease: Can Vitamin D Act as an Immunomodulator?

Authors:  Daniel S Smyk; Athanasios Mavropoulos; Giorgina Mieli-Vergani; Diego Vergani; Marco Lenzi; Dimitrios P Bogdanos
Journal:  Can J Gastroenterol Hepatol       Date:  2018-06-26

Review 3.  The Gut-Liver Axis in Cholestatic Liver Diseases.

Authors:  Andreas Blesl; Vanessa Stadlbauer
Journal:  Nutrients       Date:  2021-03-21       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.